Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Infectivity-Enhanced, Conditionally Replicative Adenovirus for COX-2-Expressing Castration-Resistant Prostate Cancer

Viruses(2023)10.3390/v15040901Source: DataRank Database

Infectivity-Enhanced, Conditionally Replicative Adenovirus for COX-2-Expressing Castration-Resistant Prostate Cancer is a research paper published in Viruses (2023). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 1.75)OA: goldTopics (52)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Naohiko Nakamura ORCID,Julia Davydova ORCID,Emmanuel S. Antonarakis ORCID,Masato Yamamoto ORCID,Tatyana Gavrikova

Live enrichment

PubMed:37112881 PMC:PMC10144787 OpenAlex:https://openalex.org/W4362468982

NCI NIH HHS

Grant: R01 CA276480

NCI NIH HHS

Grant: R01 CA228760

National Institutes of Health

Grant: 1R01CA228760-01A1

Combination therapy with IFN expressing oncolytic adenovirus for pancreatic cancer

National Institutes of Health

Grant: 5S21MD000104-07

Endowment for Disparities Research At Meharry Medical College

National Institutes of Health

Grant: 1R01CA276480-01

Advanced Oncolytic Adenovirus Enabling Systemic Therapy of PDAC

DOD PCRP DAMD17-03-1-0104

NIH/NCI R01CA276480

NIH/NCI R01CA228760

FWCI

1.75

Citation Percentile

0.9%

Citation Trend

2024

2025

goldLicense: cc-by

journalhttps://www.mdpi.com/1999-4915/15/4/901/pdf?version=1680762674

publisherhttps://www.mdpi.com/1999-4915/15/4/901/pdf?version=1680762674

publisherhttps://www.mdpi.com/1999-4915/15/4/901/pdf

journalhttps://doi.org/10.3390/v15040901

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37112881

Fields of Study

Virus-based gene therapy researchProstate Cancer Treatment and ResearchCancer Research and Treatments03 medical and health sciences0302 clinical medicineHumansMaleAdenoviridaeCyclooxygenase 2Prostatic Neoplasms, Castration-ResistantVirus ReplicationCell LineCell Line, Tumor

MeSH Terms

AdenoviridaeCell LineHumansMaleVirus ReplicationCell Line, TumorCyclooxygenase 2Prostatic Neoplasms, Castration-Resistant

Keywords

InfectivityProstate cancerIn vivoCancer researchCell cultureIn vitroBiologyVirologyCancerMedicineInternal medicineVirusBiochemistryCyclooxygenaseVirotherapyCastration ResistantAdenoviralNepcReplicativeNeuroendocrinal Prostate CancerMaleVirus ReplicationMicrobiologyQR1-502ArticleAdenoviridaeCell LineProstatic Neoplasms, Castration-ResistantCyclooxygenase 2Cell Line, TumorHumans

Sustainable Development Goals

SDG 0: No poverty